A Phase 1 Study of Natural Killer Cells Plus Atezolizumab in People With Acute Myelogenous Leukemia

Full Title

Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined with Atezolizumab in Subjects with Relapsed or Refractory Acute Myelogenous Leukemia

Purpose

Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.

The cell therapy is called cytokine-induced memory-like (CIML) natural killer (NK) cells. CIML-NK cells are made in a lab from human healthy blood from a haploidentical donor. Haploidentical means the donor’s cells are half-matched to your cells.

The healthy donor blood cells will be collected to separate out NK cells. These white blood cells play an important role in the body’s immune system. The NK cells will then be activated by immune proteins called cytokines. Cytokines can make the NK cells better at killing cancer cells.

Researchers think CIML-NK cells can kill leukemia cells while leaving normal healthy blood cells unharmed. When your CIML-NK cells are ready for you, you will receive atezolizumab in combination with the cell therapy.

Who Can Join

To join this study, there are a few conditions. You must:

• Have AML that keeps growing even after treatment.
• Have a half-matched donor who can provide blood cells for you.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 to 70 years old.

Contact

For more information and to see if you can join this study, please call Dr. Brian Shaffer’s office at 646-608-2091.